Theraclion Announces the Success of Its Capital Increase

Regulatory News:

This document may not be distributed, directly or indirectly, in the United States, Canada, Australia or Japan.

THERACLION (ISIN: FR0010120402; Mnemo: ALTHE), an innovative company developing a scalable robotic platform for non-invasive ultrasound therapy, announces today the final signature of the strategic agreement with its long-standing partner Furui, and the completion of an issue of new shares, for a total gross amount of 8.4 million euros, with 1.3 additional million euros in warrants attached in the event of exercise.

This agreement and the financing provided enable Theraclion's new CEO, Martin Deterre, to give a new impulse to the execution of his 3-pronged strategy:

• Obtain FDA market approval for SONOVEIN in the U.S. by 2025, via the launch of a pivotal multicenter study in the coming months.
• Rapid access of the SONOVEIN to the high-potential Chinese market and development of industrial capacity in China, in close partnership with Furui.
• The pursuit of technological innovations in artificial intelligence and robotics, in order to increase the speed and simplification of treatments, guaranteeing greater profitability for each machine.

Martin Deterre, Chief Executive Officer of Theraclion, comments: "Since obtaining market authorization in 2019, treatment times have been drastically reduced and nearly 2,000 treatments carried out with a success rate now close to established methods. The completion of this capital increase, the conclusion of the partnership with Furui and optimized expense management give Theraclion the means to accelerate the implementation of its value-creating strategy."

Strategic agreement with Furui finalized

Under the strategic agreement, the final details of which were finalized this week, Furui is investing 7 million euros, including 6 million euros in the capital increase and 1 million euros through the exercise of milestone warrants, via its subsidiary Furui Paris. With its expertise in supporting innovative medical companies, Furui should facilitate Theraclion's international development in its 3 strategic areas. Theraclion and Furui will work together to establish production capacity in China for Echopulse and SONOVEIN. Theraclion will grant Theraclion China, of which Furui is a co-shareholder, the license to use its technologies and trademarks in China, in return for a payment of 3 million euros linked to the achievement of specific targets.